NBSE

NeuBase Therapeutics, Inc. [NBSE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

NBSE Stock Summary

Top NBSE Correlated Resources

NBSE


Top 10 Correlated ETFs

NBSE


Top 10 Correlated Stocks

NBSE


In the News

09:08 29 Mar 2024 NBSE

Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?

NeuBase Therapeutics (NASDAQ: NBSE ) stock is falling on Tuesday after the company announced details for an upcoming special shareholder meeting. The big news here is that NeuBase Therapeutics is seeking shareholder approval for the liquidation and dissolution of the company.

12:00 29 Mar 2024 NBSE

Cheap Penny Stocks To Buy Now? 3 For Your Watch List

Penny stocks remain an alluring yet high-risk asset class for many novice investors. With share prices under $5, penny stocks appear affordable but bring higher volatility.

12:47 29 Mar 2024 NBSE

NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake

With NeuBase (NBSE) exploring strategic alternatives to the company, Symetryx joins the company's shareholder base and urges the board to issue a unique $1 per share dividend.

08:04 29 Mar 2024 NBSE

Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?

NeuBase Therapeutics (NASDAQ: NBSE ) stock is taking off on Wednesday despite a lack of news from the preclinical biopharmaceutical company. There are no new press releases from NeuBase Therapeutics or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.

05:00 29 Mar 2024 NBSE

NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting

PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepted for two oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting, which will take place in Los Angeles, CA and virtually on May 16-20, 2023.

01:32 29 Mar 2024 NBSE

What Makes NeuBase (NBSE) a New Strong Buy Stock

NeuBase (NBSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

07:32 29 Mar 2024 NBSE

New Strong Buy Stocks for January 20th

NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.

11:13 29 Mar 2024 NBSE

Best Penny Stocks To Buy? 10 Under $1 To Watch This Week

Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?

12:45 29 Mar 2024 NBSE

Best Penny Stocks To Buy? 6 Under $1 To Watch Now

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy?

01:33 29 Mar 2024 NBSE

NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce

NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing.

NBSE Financial details

Company Rating
Buy
Market Cap
3.84M
Income
-14.31M
Revenue
0
Book val./share
3.31
Cash/share
4.56
Dividend
-
Dividend %
-
Employees
37
Optionable
No
Shortable
Yes
Earnings
28 Mar 2024
P/E
-0.14
Forward P/E
-0.18
PEG
0.02
P/S
-
P/B
0.22
P/C
0.1
P/FCF
-0.18
Quick Ratio
2.7
Current Ratio
2.87
Debt / Equity
0.58
LT Debt / Equity
0.53
-
-
EPS (TTM)
-8.14
EPS next Y
-2.42
EPS next Q
1.57
EPS this Y
12.82%
EPS next Y
-70.27%
EPS next 5Y
-77.27%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-67.65%
-
-
-
-
SMA20
2.44%
SMA50
25.37%
SMA100
29.23%
Inst Own
2.78%
Inst Trans
9.59%
ROA
-77%
ROE
-108%
ROC
-1.09%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
3.73M
Shs Float
3.03M
-
-
-
-
Target Price
-
52W Range
0.59-5.4
52W High
-
52W Low
-
RSI
25.21
Rel Volume
1.33
Avg Volume
207.48K
Volume
275.64K
Perf Week
-56.89%
Perf Month
-32.84%
Perf Quarter
-40.61%
Perf Half Y
-44.5%
-
-
-
-
Beta
1.013
-
-
Volatility
0.29%, 0.17%
Prev Close
2.14%
Price
0.444
Change
-7.5%

NBSE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-09-30

Metric History 2018-09-302019-09-302020-09-302021-09-30 2022-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-93.57-65.49-17.6-18.8-21.21
Operating cash flow per share
-67.1-6.88-10.92-13.82-17.97
Free cash flow per share
-67.1-8.22-11.65-14.88-18.27
Cash per share
26.5124.9432.6138.7414.34
Book value per share
77.0624.2531.939.614.37
Tangible book value per share
23.2523.931.939.614.37
Share holders equity per share
77.0624.2531.939.614.37
Interest debt per share
-4.20.610.154.823.73
Market cap
10.83M41.28M148.92M98.57M12.75M
Enterprise value
7.15M31.08M117.06M52.22M-4.41M
P/E ratio
-0.82-1.52-8.63-3.84-0.37
Price to sales ratio
00000
POCF ratio
-1.14-14.51-13.9-5.22-0.44
PFCF ratio
-1.14-12.15-13.03-4.85-0.43
P/B Ratio
0.994.124.761.820.55
PTB ratio
0.994.124.761.820.55
EV to sales
00000
Enterprise value over EBITDA
-2.29-1.19-6.92-2.010.14
EV to operating cash flow
-0.75-10.92-10.93-2.770.15
EV to free cash flow
-0.75-9.15-10.24-2.570.15
Earnings yield
-1.22-0.66-0.12-0.26-2.68
Free cash flow yield
-0.88-0.08-0.08-0.21-2.31
Debt to equity
0.010.0100.120.26
Debt to assets
0.010.0100.10.18
Net debt to EBITDA
1.180.391.881.790.53
Current ratio
5.524.4110.4213.15.92
Interest coverage
20.84-204.24-2.22K-821.7-1.39K
Income quality
0.720.110.620.740.86
Dividend Yield
00.01000
Payout ratio
0-0.02000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.650.01000
Capex to operating cash flow
00.190.070.080.02
Capex to revenue
00000
Capex to depreciation
0-4.31-2.56-3.57-0.37
Stock based compensation to revenue
00000
Graham number
402.79189.04112.38129.4382.81
ROIC
-2.13-2.61-0.54-0.4-0.96
Return on tangible assets
-3.3-2.19-0.5-0.4-1.05
Graham Net
21.3918.8929.431.358.48
Working capital
3.27M8.53M29.66M50.73M20.48M
Tangible asset value
3.29M9.88M31.29M54.07M23.19M
Net current asset value
3.27M8.53M29.66M44.83M15.15M
Invested capital
0.010.0100.120.26
Average receivables
000063.86K
Average payables
0738.58K1.49M1.66M1.83M
Average inventory
0000-63.86K
Days sales outstanding
00000
Days payables outstanding
04.2K1.96K1.15K532.83
Days of inventory on hand
0000-36.92
Receivables turnover
00000
Payables turnover
00.090.190.320.69
Inventory turnover
0000-9.89
ROE
-1.21-2.7-0.55-0.47-1.48
Capex per share
0-1.34-0.73-1.05-0.29

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q4

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-4.67-3.04-2.4-2.04-0.66
Operating cash flow per share
-4.11-3.45-2.06-2.15-0.73
Free cash flow per share
-4.13-3.48-2.06-2.15-0.73
Cash per share
14.3410.538.258.714.56
Book value per share
14.3711.048.616.643.31
Tangible book value per share
14.3711.048.616.643.31
Share holders equity per share
14.3711.048.616.643.31
Interest debt per share
3.723.493.353.231.93
Market cap
12.75M6.27M6.21M3.17M2.4M
Enterprise value
-4.41M-5.35M-2.02M-6.11M-4.84M
P/E ratio
-0.42-0.31-0.39-0.23-0.33
Price to sales ratio
00000
POCF ratio
-1.92-1.1-1.8-0.87-1.2
PFCF ratio
-1.91-1.09-1.79-0.87-1.2
P/B Ratio
0.550.340.430.280.26
PTB ratio
0.550.340.430.280.26
EV to sales
00000
Enterprise value over EBITDA
0.61.580.531.341.72
EV to operating cash flow
0.660.940.591.682.42
EV to free cash flow
0.660.930.581.682.42
Earnings yield
-0.59-0.8-0.65-1.09-0.76
Free cash flow yield
-0.52-0.91-0.56-1.15-0.83
Debt to equity
0.260.320.390.490.58
Debt to assets
0.180.230.260.250.29
Net debt to EBITDA
2.353.422.172.032.57
Current ratio
5.928.377.42.532.87
Interest coverage
-2.87K-2.46K-1.77K-5.05K23.06K
Income quality
0.871.30.841.061.1
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.01000
Capex to revenue
00000
Capex to depreciation
-0.09-0.16-0.0400
Stock based compensation to revenue
00000
Graham number
38.8627.4921.5617.457.02
ROIC
-0.22-0.18-0.16-0.1-0.12
Return on tangible assets
-0.23-0.2-0.19-0.15-0.1
Graham Net
8.486.224.112.161.12
Working capital
20.48M15.82M12.29M9.39M8.7M
Tangible asset value
23.19M18.22M14.45M11.25M9.14M
Net current asset value
15.15M10.61M7.2M4.43M3.87M
Invested capital
0.260.320.390.490.58
Average receivables
63.86K138.86K75.08K750
Average payables
1.75M1.11M479.85K456.16K290.39K
Average inventory
-63.86K63.79K182.31K54.66K0
Days sales outstanding
00000
Days payables outstanding
494.460176.7895.3893.02
Days of inventory on hand
-34.26032.7500
Receivables turnover
00000
Payables turnover
0.1800.510.940.97
Inventory turnover
-2.6302.7500
ROE
-0.33-0.28-0.28-0.31-0.2
Capex per share
-0.02-0.03-0.0100

NBSE Frequently Asked Questions

What is NeuBase Therapeutics, Inc. stock symbol ?

NeuBase Therapeutics, Inc. is a US stock , located in Pittsburgh of Pa and trading under the symbol NBSE

What is NeuBase Therapeutics, Inc. stock quote today ?

NeuBase Therapeutics, Inc. stock price is $0.444 today.

Is NeuBase Therapeutics, Inc. stock public?

Yes, NeuBase Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap